Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech IPO:
Ab&B Bio-Tech, a Chinese vaccine biotech company, has filed for an initial public offering (IPO) in Hong Kong, aiming to raise funds for further development and commercialization of its vaccine products3.
Industry Competition:
The move draws attention from major pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, and Pfizer, which are also active in the vaccine and biotechnology sectors35.
Market Context:
The IPO comes at a time when the biotech industry is seeing significant activity, with companies like Moderna and ADC Therapeutics also making recent IPO announcements14.
Strategic Alliances:
GSK and Merck have previously collaborated on immunotherapy projects, such as the development of M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers2.
Pfizer’s Recent Moves:
Pfizer has been actively acquiring and developing new biotech assets, including its recent acquisition of Arena Pharmaceuticals and the discontinuation of certain mid-stage medicines to focus on more promising projects5.
Sources:
1. https://slidebean.com/story/history-of-airbnb
2. https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-kgaa-darmstadt-germany-announce-global-alliance-to-jointly-develop-and-commercialise-m7824-a-novel-immunotherapy-with-potential-in-multiple-difficult-to-treat-cancers/
3. https://www.cafepharma.com/content/gsk-merck-and-pfizer-abb%E2%80%99s-sights-chinese-vaccine-biotech-files-ipo
4. https://theedgemalaysia.com/article/tech-why-airbnbs-ipo-may-have-lot-room-run
5. https://www.fiercebiotech.com/biotech/pfizer-tosses-newly-acquired-meds-out-arena-part-midstage-cleaning